Senzime AB (SEZI) - Total Liabilities
Based on the latest financial reports, Senzime AB (SEZI) has total liabilities worth Skr66.51 Million SEK (≈ $7.16 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Senzime AB to evaluate the company's liquid asset resilience ratio.
Senzime AB - Total Liabilities Trend (2005–2025)
This chart illustrates how Senzime AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Senzime AB (SEZI) total assets.
Senzime AB Competitors by Total Liabilities
The table below lists competitors of Senzime AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TsannKuen (China) Enterprise Co. Ltd
SHE:200512
|
China | HK$938.16 Million |
|
Sietel Ltd
AU:SSL
|
Australia | AU$9.16 Million |
|
Quartiers Properties AB
ST:QUART
|
Sweden | Skr218.07 Million |
|
Bluebird bio Inc
NASDAQ:BLUE
|
USA | $353.82 Million |
|
Green Cross Medical Science Corporation
KQ:142280
|
Korea | ₩40.86 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr13.56 Million |
|
Iskandar Waterfront City Bhd
KLSE:1589
|
Malaysia | RM636.26 Million |
|
Indonesia Energy
NYSE MKT:INDO
|
USA | $3.28 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Senzime AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Senzime AB to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Senzime AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Senzime AB (2005–2025)
The table below shows the annual total liabilities of Senzime AB from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr65.35 Million ≈ $7.03 Million |
-16.94% |
| 2024-12-31 | Skr78.67 Million ≈ $8.47 Million |
+35.49% |
| 2023-12-31 | Skr58.06 Million ≈ $6.25 Million |
-4.46% |
| 2022-12-31 | Skr60.78 Million ≈ $6.54 Million |
+152.80% |
| 2021-12-31 | Skr24.04 Million ≈ $2.59 Million |
-12.72% |
| 2020-12-31 | Skr27.55 Million ≈ $2.96 Million |
+14.45% |
| 2019-12-31 | Skr24.07 Million ≈ $2.59 Million |
-19.10% |
| 2018-12-31 | Skr29.75 Million ≈ $3.20 Million |
+16.33% |
| 2017-12-31 | Skr25.57 Million ≈ $2.75 Million |
+4.63% |
| 2016-12-31 | Skr24.44 Million ≈ $2.63 Million |
+1126.44% |
| 2015-12-31 | Skr1.99 Million ≈ $214.46K |
-10.94% |
| 2014-12-31 | Skr2.24 Million ≈ $240.79K |
+91.47% |
| 2013-12-31 | Skr1.17 Million ≈ $125.76K |
-6.29% |
| 2012-12-31 | Skr1.25 Million ≈ $134.19K |
-67.12% |
| 2011-12-31 | Skr3.79 Million ≈ $408.17K |
-5.82% |
| 2010-12-31 | Skr4.03 Million ≈ $433.39K |
-11.76% |
| 2009-12-31 | Skr4.56 Million ≈ $491.13K |
-5.42% |
| 2008-12-31 | Skr4.83 Million ≈ $519.27K |
+11.44% |
| 2007-12-31 | Skr4.33 Million ≈ $465.98K |
+34.39% |
| 2006-12-31 | Skr3.22 Million ≈ $346.74K |
+7.22% |
| 2005-12-31 | Skr3.00 Million ≈ $323.39K |
-- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more